FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Marketing

New DTC Major Statement Standards Become Effective

New FDA advertising standards require drug marketers to ensure their direct-to-consumer advertisements major statement is presented in a clear, conspi...

latest-news-card-1
Biologics

Preserve Covid-19 Vaccine Records: Senator

Republican Sen. Ron Johnson orders FDA, HHS, and CDC to preserve all records relating to Covid-19 vaccines, saying they will be subpoenaed if they are...

latest-news-card-1
Human Drugs

CDER Deputy Throckmorton Retiring in January

CDER deputy director for regulatory programs Doug Throckmorton announces his retirement after 27 years at the agency.

latest-news-card-1
Human Drugs

Toms of Maine CGMP Issues

FDA warns the Colgate-Palmolive Toms of Maine unit about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Federal Register

Cell/Gene Therapy Product Frequent Questions

Federal Register notice: FDA makes available a draft guidance entitled Frequently Asked Questions Developing Potential Cellular and Gene Therapy Prod...

latest-news-card-1
Federal Register

Jesduvroq Not Withdrawn Over Safety/Efficacy

Federal Register notice: FDA determines that GlaxoSmithKlines Jesduvroq (daprodustat) tablets were not withdrawn due to safety or effectiveness reason...

latest-news-card-1
Medical Devices

Advisors Asked About Generative AI Regulation

FDA asks members of its Digital Health Advisory Committee to spend two days discussing agency questions about its role in regulating generative artifi...

latest-news-card-1
Human Drugs

Astellas Gets Complete Response on Izervay sNDA

FDA sends Astellas Pharma a complete response letter on a supplemental NDA for Izervay (avacincaptad pegol intravitreal solution) seeking revised drug...

latest-news-card-1
Human Drugs

Stakeholder Comments on Oncology Trial Guidance

Three stakeholders raise concerns about an FDA draft guidance on considerations for generating clinical evidence from multiregional clinical developme...

latest-news-card-1
Human Drugs

Subcutaneous Keytruda is Noninferior to IV Formulation: Merck

Merck reports positive topline results from a trial that evaluated the noninferiority of subcutaneous administration of Keytruda (pembrolizumab) versu...